A Medicine Made for One Baby

Doctors built a personalized CRISPR base-editing therapy for an infant with a lethal rare disorder in about six months. The case offers a possible template for diseases too rare to support a conventional drug program.

7 sources / Updated August 26, 2026

WebPenn MedicinePenn MedicineWorld's first patient treated with personalized CRISPR therapyClinical team's account of KJ's diagnosis, rapid custom base-editor development, dosing, early outcome, collaborators, and funding.Read original
What changed
A CHOP and Penn team designed, tested, cleared, and administered an in-vivo base-editing therapy matched to one infant's CPS1 mutation. The treatment used lipid nanoparticles to reach liver cells and a custom guide to correct the harmful DNA letter. KJ tolerated several doses, increased dietary protein, and handled viral illnesses without the severe ammonia crisis clinicians feared. The larger advance is organizational: researchers reused known components while changing the sequence-specific part for one urgent patient.
WebNew England Journal of MedicineNew England Journal of MedicinePatient-Specific In Vivo Gene Editing to Treat a Rare Genetic DiseasePeer-reviewed case report describing therapy design, regulatory preparation, dosing, biochemical response, safety observations, and limits.Read original
What remains unproved
One child's early response cannot establish durable benefit, late side effects, or safety across other genes and organs. Editing efficiency varies by genomic target, and many disorders cannot be reached with the same liver-directed delivery system. Each custom sequence still needs design, manufacturing, quality checks, preclinical evidence, regulatory review, and long follow-up. Cost and access could remain severe barriers. The result supports a platform idea, but it does not mean clinicians can now order bespoke CRISPR treatments on demand.
WebNational Institutes of HealthNational Institutes of HealthInfant receives first personalized gene-editing treatmentFederal research summary explaining the reusable platform concept, the disease mechanism, early clinical response, and NIH support.Read original
What to watch
Follow KJ's long-term liver function, development, immune response, off-target monitoring, medication needs, and any later adverse effects. Beyond this case, watch for additional patients treated through shared manufacturing and regulatory processes rather than wholly separate programs. A credible platform should shorten design-to-dose time while preserving independent review and full quality control. Public evidence on cost, failed candidates, and mutations that cannot be edited will matter as much as the next successful treatment.
WebAssociated PressAssociated PressGene editing helped a desperately ill baby thriveIndependent report placing the result in the context of rare-disease medicine and the practical barriers to repeating it for other families.Read original

Loading collection…

What changed

What remains unproved

What to watch